Ersan Horoz

Ersan Horoz

Auto-generated profile, based on publicly available information

Ersan Horoz

Department of Pharmacology and Toxicology Izmir Kâtip Celebi University Faculty of Medicine Izmir Türkiye

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2022 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
BKBaris Karadas
Baris Karadas
SASelin Acar-Sahan
Selin Acar-Sahan
SKSercan Kantarci
Sercan Kantarci
NUNusret Uysal
Nusret Uysal
EHErsan Horoz
Ersan Horoz
TKTijen Kaya-Temiz
Tijen Kaya-Temiz

24 April 2024 in Toxicon
Verified
Journal Article
Closed access
IYIsmail Yilmaz
Ismail Yilmaz
IAIlgaz Akata
Ilgaz Akata
EHErsan Horoz
Ersan Horoz
EKErtugrul Kaya
Ertugrul Kaya


14 August 2023 in Fetal and Pediatric Pathology
Verified
Journal Article
Closed access
MŞMustafa Şengül
Mustafa Şengül
BKBaris Karadas
Baris Karadas
SASelin Acar-Sahan
Selin Acar-Sahan
FSFatma Simsek
Fatma Simsek
EHErsan Horoz
Ersan Horoz
TTTijen Temiz
Tijen Temiz
Objective: To investigate the relaxation responses mediated by L-type Ca2+ channels and big-conductance Ca2+-activated K+ (BKCa) channels and histological changes in the human umbilical artery (HUA) and myometrium smooth muscle isolated from pregnancies complicated with intrauterine growth restriction (IUGR).Methods: The muscle reactivity and the histology of the smooth muscle of the HUA and myometrium retrieved from 14 women with IUGR and 14 controls were investigated by the isolated tissue bath and immunohistochemical method.Results: In HUA, the maximum relaxation responses and pD2 values of nifedipine and NS11021 (BKCa channel opener) were significantly increased and significant histopathological changes are observed in the IUGR group.Conclusions: The pathogenesis of IUGR might be associated with the impairment in the functional responses of L-type Ca2+ channels and BKCa channels in HUA smooth muscle. The increased staining of myometrium and UC with HIF-1α in IUGR may indicate apoptosis, histological damage, and impaired fetal growth.

6 May 2026 in Breastfeeding Medicine
Verified
Journal Article
Closed access
BEBurak Eskiyurt
Burak Eskiyurt
EHErsan Horoz
Ersan Horoz
DBDeniz Ceyda Bakırlı
Deniz Ceyda Bakırlı
MGMesut Gungor
Mesut Gungor
BKBaris Karadas
Baris Karadas
YKYusuf Cem Kaplan
Yusuf Cem Kaplan
Background: Etanercept is a tumor necrosis factor inhibitor frequently used to control ankylosing spondylitis (AS) in women of reproductive age, yet data on its safety during breastfeeding are limited. We report a case of an infant who developed somnolence, hypotonia, feeding difficulties, and a concomitant infection temporally associated with maternal etanercept therapy during lactation and discuss implications for breastfeeding. Case: A 33-year-old woman with AS delivered a healthy female infant by cesarean section at 36 + 5 weeks’ gestation and began exclusive breastfeeding. At 11 weeks postpartum, she initiated etanercept 25 mg subcutaneously once weekly for her active disease. During treatment, the infant developed prolonged sleep, somnolence, feeding difficulty, and hypotonia, followed within a week by low-grade fever, cough, and nasal congestion. After three doses, etanercept was discontinued, and she was referred to our teratology information service. Approximately 2 weeks after the last dose, the infant’s respiratory symptoms worsened, and diarrhea developed, prompting emergency admission. Laboratory evaluation showed leukocytosis, elevated C-reactive protein, and a nasopharyngeal swab, which was positive for rhinovirus/enterovirus. Symptoms resolved with supportive care and azithromycin by treatment days 4–5. At 9 months of age, the infant has had no other health issues. Conclusions: This case illustrates the difficulty of interpreting adverse events in breastfed infants exposed to maternal biologic medications. Although current evidence suggests no clinically severe adverse effects, minimal infant exposure, and a low risk of clinically relevant immunosuppression with etanercept during breastfeeding, individualized counseling and careful monitoring of exposed infants remain essential.

1 November 2026 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
DBDeniz Ceyda Bakirli
Deniz Ceyda Bakirli
EHErsan Horoz
Ersan Horoz
CKCagri Caglayan Kuragi
Cagri Caglayan Kuragi
MGMesut Gungor
Mesut Gungor
OKOsman Karakulak
Osman Karakulak
YKYusuf Cem Kaplan
Yusuf Cem Kaplan